This move is archived. Current quotes and coverage live on the stock page.
Follow BCT
Briacell Therapeutics Corp's stock surged by over 7% in the latest trading session, driven by strategic developments in its clinical pipeline.
In the latest trading session, Briacell Therapeutics Corp (BCT.TO) saw its stock price jump by 7.11%, closing at CA$5.27. This increase is due to the company's recent collaboration with consulting firms to improve its commercial strategy for the promising cancer therapy, Bria-IMT.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$38.86M
52W high
$18.00
52W low
$3.68
1W change
-8.44%
Beta
1.66
Analyst Price Targets
Based on analyst covering BCT · as of Sep 17, 2026
Wall Street analysts forecast BCT stock price to rise 333.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+333.8% Upside
Current Price
C$4.61
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
62.6%
Annualized
90-Day Vol
73.5%
Annualized
Trend (90d)
-15.2%
Annualized drift
90d Mean
C$4.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.53 | C$3.65 – C$5.62 |
| 60 trading days | C$4.45 | C$3.28 – C$6.03 |
| 90 trading days | C$4.37 | C$3.00 – C$6.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are responding positively to Briacell's proactive approach in preparing for the potential commercialization of Bria-IMT, which is currently in a crucial Phase 3 study for metastatic breast cancer.
Briacell Therapeutics Corp's stock rises 7.11%
With a market cap of approximately CA$43.15 million, Briacell's recent developments could signal a shift in investor sentiment towards biotech stocks focused on innovative cancer therapies.
Bull case
The involvement of Charles River Associates and Kaleio shows strong confidence in Bria-IMT's potential. This positions Briacell well for future market access and commercialization, which could significantly boost its valuation.
Bear case
Even with the positive momentum, investors should stay cautious. Bria-IMT is still in clinical trials and hasn’t received regulatory approval yet, which carries inherent risks.
Strategic Partnerships Fuel Growth
Briacell's recent collaboration with Charles River Associates and Kaleio is a strategic move to assess the market potential of its Bria-IMT therapy. This partnership aims to improve the company's understanding of prescriber dynamics and pricing strategies, both essential for successful commercialization.
Market Reaction and Future Prospects
The stock's positive movement reflects investor optimism about Briacell's future. As the company continues its pivotal Phase 3 study, successful outcomes could lead to significant advancements in treatment options for metastatic breast cancer, increasing investor confidence.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
